Recent Updates
Recently added Catalysts
BMY Positive Sentiment

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tempus AI, Inc. has entered into a multi-year agreement with Bristol Myers Squibb, allowing BMS to license oncology data from Tempus through 2031. This collaboration aims to enhance biological and clinical insights, aiding in drug target discovery and therapeutic development within BMS's oncology portfolio. The partnership marks a significant expansion of their strategic relationship.

Market Sentiment Analysis

POSITIVE FACTORS

  • BMS expands its strategic collaboration with Tempus.
  • The agreement supports drug target discovery and therapeutic development.
  • Tempus provides multimodal oncology data until 2031.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+17%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
CC-95266
Phase 1 · Multiple Myeloma

Full Press Release Details

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest li

Frequently Asked Questions

What is the purpose of the Tempus and BMS collaboration?

The collaboration aims to enhance biological insights and support drug target discovery.

How long will the agreement between Tempus and BMS last?

The agreement will last until 2031.

What type of data will BMS license from Tempus?

BMS will license multimodal oncology data.

What is the significance of this agreement for BMS?

It significantly expands BMS's strategic relationship with Tempus.

ShareAdd on Google
Tags: BMY Tempus Bristol Myers Squibb oncology data drug discovery therapeutic development
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$11464M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CC-95266Phase 1
Multiple Myeloma →

Catalyst track record

+17%
best trade around BMY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for BMY.

See every catalyst's timing & PoA →